US Stock Insider Trading | Zentalis Discloses 7 Insider Transactions on February 10

K-LinePoet · 2026-02-14T07:36:33+00:00

Zentalis (ZNTL) disclosed multiple insider transactions on February 10, 2026. Executive Vultaggio Vincent sold over 10,000 shares on February 6 and 9, with transaction prices ranging from $2.39 to $2.55. The company focuses on developing novel small-molecule anti-cancer therapies.

K-LinePoet

2026-02-14 07:36:33

Abstract generation in progress

On February 10, 2026, Zentalis (ZNTL) disclosed seven insider trading transactions. Executive Vultaggio Vincent sold 30,000 shares on February 10, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 10, 2026	Executive	Vultaggio Vincent	February 6, 2026	Sell	30,000	2.43	72,800
February 10, 2026	Director	EASTLAND JULIA MARIE	February 9, 2026	Sell	889	2.39	2,127.29
February 10, 2026	Executive	Bruns Ingmar	February 6, 2026	Sell	2,962	2.43	7,196.77
February 10, 2026	Executive	Vultaggio Vincent	February 9, 2026	Sell	3,379	2.39	8,085.61
February 10, 2026	Executive	Vultaggio Vincent	February 10, 2026	Sell	6,894	2.42	16,700
February 10, 2026	Director	EASTLAND JULIA MARIE	February 6, 2026	Sell	7,866	2.43	19,100
February 10, 2026	Executive	Bruns Ingmar	February 9, 2026	Sell	335	2.39	801.62
February 4, 2026	Executive	Vultaggio Vincent	February 3, 2026	Sell	556	2.52	1,398.34
February 4, 2026	Executive	Vultaggio Vincent	February 2, 2026	Sell	2,540	2.55	6,477.00
January 8, 2026	Shareholder with over 10% ownership	WALTERS GROUP	December 31, 2025	Buy	6.46 million	1.20	7,752,000

[Company Information]

Zentalis Pharmaceuticals, Inc. was incorporated in Delaware on December 23, 2014, as Zeno Pharmaceuticals, Inc. Zentalis Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing novel small-molecule therapies targeting fundamental biological pathways in cancer.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.